Study summary

A JAK1 pill produced responses in 44% of people with relapsed disease

JACKPOT8 trial (golidocitinib) · 104 people, phase 2 · Published December 2023, Lancet Oncology

44.3%response rate

What was tested

Golidocitinib, a selective JAK1 inhibitor, for relapsed or refractory peripheral T-cell lymphoma.

What they found

Response rate was 44.3%, with complete responses in 24%.
Serious drug-related side effects occurred in 59%, mostly low blood counts.

What it means

Approved in China; a global phase 3 trial against standard choices is now under way.

Lancet Oncol, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.